• Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

ESG Reports

ESG Report
FY 2023-24

ESG Report
FY 2022-23

View the interactive version of our ESG report

ESG Report
FY 2021-22

ESG Report
FY 2020-21

ESG Report
FY 2022-23

View the interactive version of our ESG report

ESG Report
FY 2021-22

Investor Fact Sheet

Financial Information

Annual Reports

Syngene collaborates with biotech firm to develop bile acid modulator for cholestatic disease treatment
Syngene Results Q4 FY25 and full-year FY25

Investor Calendar

Conference Call For Analysts And Investors

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details